Clinical Trial: De-escalation of Axillary Dissection for Node-positive Breast Cancer

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07856160) titled 'De-escalation of Axillary Dissection for Node-positive Breast Cancer' on Sept. 28.

Brief Summary: Recent studies have demonstrated the safety of de-escalation of nodal surgery for clinically node-positive breast cancer patients after a favorable response to neoadjuvant systemic therapy (NST). These studies excluded patients with clinically node-positive stage 2 or 3 (cN2, cN3) disease. Consequently, the current guidelines recommend axillary lymph node dissection (ALND) for patients with cN2/cN3 breast cancer, even after a favorable response to NST. Many cN2/cN3 patients achieve nodal pathologic complete response (pCR) after NST, and ...